China Even though China’s pharmaceutical sector remains largely generics-based, the Middle Kingdom’s biotechnology scene has been flourishing in recent years. Now the world’s fastest-growing biopharmaceutical market, China can boast a much-improved context in terms of drug regulation, ease of doing business, research capabilities and access to capital. Below, we highlight 5…

China In late 2018 China adopted a novel procurement scheme with the aim of dramatically cutting the amount being paid for generic drugs. The policy’s effect on pricing stands to hit domestic generic firms hardest unless they adapt their business models. Big Pharma could also lose out as their off-patent originators…

China China is set to become the second largest market for Mundipharma’s OxyContin behind the US.   It comes as no surprise that sales of opioids such as OxyContin have plummeted in the US following the media storm around the opioid crisis that sees the loss of thousands of American lives…

Genomics Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis and Kevin Allison is the director of geo-technology. Together they look at last week’s shock revelation of two CRISPR* babies who were born in China and the added tensions this might cause with the USA.    Aside from the immediate implications for US-China strategic competition, the…

China Following China’s vaccine scandal earlier this year, the country’s drug administration has considerably tightened up inspection processes of vaccine manufacturers which is causing shortages and raising the risk of widespread flu infection.   In July this year, Chinese vaccine producer Changsheng Biotechnology (who account for 15 percent of China’s flu…

China China’s stupendous economic resurgence over the past four decades never ceases to awe, but what has captured attention in recent years has been the country’s international awakening. Against a nasty backdrop of intensifying populist nationalism, right-wing radicalism and trade protectionism in many advanced economies, Chinese President Xi Jinping’s surprising 2017…

China Cash has always ruled the start-up world and when it comes to the healthcare and life sciences sphere, the heavy investment required for R&D and the long timelines make it even more so. Luckily, China is now the second-largest VC market in the world, and a recent Preqin report highlighted that USD 65…

China The Greater Bay Area’s – and in particular, Shenzhen’s – prowess in life sciences manufacturing and development must also be attributed to the decades of experience and expertise gained from acting as OEM/ODM to global companies, in line with China’s overall positioning as the world’s factory floor. One of the…

China In 2013, Chinese President Xi Jinping launched the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) initiative, corralling the two Special Administrative Regions (SARs) of Hong Kong and Macao with Guangdong, one of the richest of China’s 34 provinces. While the official government blueprint was due to be unveiled in mid-2018, escalating…

China Professor Richard Barker, founder of New Medicine Partners reflects on China’s very different approach to the biopharma industry.   Napoleon once said: “China is a sleeping giant. Let her sleep, for when she wakes she will shake the world.” Well, in biotech, she is now wide awake I’ve recently returned from…

regulation Chinese ecommerce behemoths Alibaba and JD.com are being used to buy and sell tens of thousands of prescription medicines, skirting regulations in what is a legal grey area. According to a recent Financial Times report, dozens of listings from third party vendors – mainly pharmacies – for drugs such as…

China This week, China has fast-tracked approval for 48 “much-needed medicines.” Regulators gave special consideration to new treatments for rare diseases as well as drugs that target serious, life-threatening illnesses, like cancer. Authorities were made to sit up and listen following the box office success of a low budget film called “Dying to…